Cargando…

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()

OBJECTIVES: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing medroxyprogesterone acetate (MPA) as an active ingredient. STUDY DESIGN: We conducted a randomized, crossover, single-center study. Twent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpern, Vera, Wheeless, Angie, Brache, Vivian, Lendvay, Anja, Cochón, Leila, Taylor, Douglas, Dorflinger, Laneta J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562734/ https://www.ncbi.nlm.nih.gov/pubmed/37823034 http://dx.doi.org/10.1016/j.conx.2023.100100

Ejemplares similares

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial
por: Halpern, Vera, et al.
Publicado: (2021)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector()
por: Liu, Jenny, et al.
Publicado: (2018)

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
por: Stout, Anna, et al.
Publicado: (2018)

Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
por: Odwe, George, et al.
Publicado: (2018)

Adolescent and covert family planning users’ experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate
por: Burke, Holly M., et al.
Publicado: (2020)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

Levonorgestrel release rates measured through analysis of two-rod contraceptive explants
por: Fuchs, Rachael, et al.
Publicado: (2020)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial
por: Deese, Jennifer, et al.
Publicado: (2022)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()
por: Smith, Tiffany Joyce, et al.
Publicado: (2023)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi
por: Porter Erlank, Chelsey, et al.
Publicado: (2023)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

Erratum for: Odwe et al., Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
Publicado: (2019)

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis
por: Nabhan, Ashraf, et al.
Publicado: (2021)

Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi
por: Burke, Holly M., et al.
Publicado: (2019)

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020)

An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract
por: Ayele, Hossaena, et al.
Publicado: (2021)

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate
por: Bradley, Frideborg, et al.
Publicado: (2022)

What Distinguishes Women Who Choose to Self-Inject? A Prospective Cohort Study of Subcutaneous Depot Medroxyprogesterone Acetate Users in Ghana
por: Nai, Dela, et al.
Publicado: (2022)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
por: Walker, Christie, et al.
Publicado: (2013)

Successful treatment of Depot Medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in Adolescents
por: Rager, Kristin M., et al.
Publicado: (2006)

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility
por: Smith-McCune, K K, et al.
Publicado: (2017)

Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
por: Yang, Liying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_883tk1l7vg2f0niv77kk2mi6no